The monthly treatment cost, based on a 2-gram twice daily administration, will be $294. is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Cardiovascular death, myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina (5-point MACE), Cardiovascular death, myocardial infarction, stroke (3-point MACE), Emergent or urgent coronary revascularization. This is the first and only approval by Health Canada of any drug for this important indication. Circ Res. Blink Health is driving down the cost of prescription drugs in America with up to 80% savings on prescription medications. Amarin’s lead product, VASCEPA® (icosapent ethyl), is available by prescription in the United States, Lebanon and the United Arab Emirates, and is expected to be available in Canada through an anticipated February 2020 commercial launch. With its strong trial results and accessible pricing, we believe Vascepa can deliver significant long-term benefit for both Canadians and our health care system.". Generic Name: icosapent ethyl Brand Name: Vascepa Manufacturer: HLS Therapeutics Therapeutic Area: Ischemic events in statin-treated patients Indications: Ischemic events in … Amarin, together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, the European Union, the Middle East and North Africa, and is evaluating other regions for potential regulatory filings. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. Journal of the American College of Cardiology. © 2021 GlobeNewswire, Inc. All Rights Reserved. In addition to milestone and supply payments, the agreement for commercialization in Canada provides for payment to Amarin of double-digit royalties on VASCEPA net sales in Canada. Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the U.S. prescribing information for VASCEPA, as set forth below: Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in Patients with Elevated Triglyceride levels and Other Risk Factors for Cardiovascular Disease in REDUCE-IT. This press release contains forward-looking statements, including expectations regarding regulatory submissions and approvals and commercialization of VASCEPA in Canada and other markets, as well as timing related thereto, potential milestone and other payments to be paid to Amarin, commercial market expectations including pricing and sales potential, the applicability and reliability of REDUCE-IT results, and cost effectiveness data expectations regarding commercial expansion and the use of VASCEPA. When typing in this field, a list of search results will appear and be automatically updated as you type. For more information visit: www.hlstherapeutics.com. All prices are as per the BC PharmaCare Drug Formulary, unless otherwise indicated. 2019;73(22):2791–802. These prices: Do not account for prescription insurance and co-pays; Apply only to those prescriptions purchased and mailed from Costco.com; Occasionally prices … New England Journal of Medicine. For more information visit: www.hlstherapeutics.com. Vascepa was developed and tested over the course of a decade and at a cost of more than $500.0 million in order to bring a new preventative care solution that may help the many family members, friends and neighbors who may be at risk for a cardiac event.
Jeremias 33 3, Digitech Longarm Quilting Designs, Hp Keyboard 100, Wildcraft Age Rating, Oven Smells Like Burning Plastic, What To Say When Someone Dies Condolences In Islam, Why Is Ty Missing From Heartland, How To Turn On Mic In Fortnite Ps4 Without Headset, Retile Discount Code,